drugset

drugset / Trial / NCT01728311

Open Label Study of BAY1082439 in Patients With Advanced Cancer

NCT01728311 ↗

Phase 1 Completed 60 enrolled Bayer

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439

Timeline

Start: 2012-11-21
Primary completion: 2016-06-03
Completion: 2017-02-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BAY1082439	Small molecule	15 mg	Oral

Indications